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Abstract: White matter lesions (WML) are a common feature of the ageing brain associated with 
cognitive impairment. The gene expression profiles of periventricular lesions (PVL, n = 7) and 
radiologically-normal-appearing (control) periventricular white matter cases (n = 11) obtained from 
the Cognitive Function and Ageing Study (CFAS) neuropathology cohort were interrogated using 
microarray analysis and NanoString to identify novel mechanisms potentially underlying their 
formation. Histological characterisation of control white matter cases identified a subgroup (n = 4) 
which contained high levels of MHC-II immunoreactive microglia, and were classified as “pre-
lesional.” Microarray analysis identified 2256 significantly differentially-expressed genes (p ≤ 0.05, 
FC ≥ 1.2) in PVL compared to non-lesional control white matter (1378 upregulated and 878 
downregulated); 2649 significantly differentially-expressed genes in “pre-lesional” cases compared 
to PVL (1390 upregulated and 1259 downregulated); and 2398 significantly differentially-expressed 
genes in “pre-lesional” versus non-lesional control cases (1527 upregulated and 871 
downregulated). Whilst histological evaluation of a single marker (MHC-II) implicates immune-
activated microglia in lesion pathology, transcriptomic analysis indicates significant 
downregulation of a number of activated microglial markers and suggests established PVL are part 
of a continuous spectrum of white matter injury. The gene expression profile of “pre-lesional” 
periventricular white matter suggests upregulation of several signalling pathways may be a 
neuroprotective response to prevent the pathogenesis of PVL. 
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1. Introduction 
Age-associated white matter lesions (WML) appear as hyperintensities on T2-weighted 
magnetic resonance images (MRI) and are frequently observed in people aged over 65 years [1]. These 
WML are often interpreted as a surrogate for small vessel disease and are associated with an 
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increased risk of dementia [2–4]; the impact of WML on cognition is related to their neuroanatomical 
locations [5]. 
WML can be subclassified as periventricular (PVL) or deep subcortical lesions (DSCL), which 
both share similar histopathological features, including myelin attenuation, axonal damage, 
astrogliosis and microglial activation, as reviewed in [6–8]. However, differences in the cellular 
pathology profiles of these WML have also been reported, particularly in relation to their microglial 
phenotype. Microglia share functions with tissue macrophages, including surveillance, antigen 
presentation and phagocytosis [9]. Previous studies suggest microglia within PVL have a 
predominantly pro-inflammatory immune reactive phenotype, associated with the expression of the 
major histocompatibility complex class II (MHC-II) and co-stimulatory molecule B7-2 (CD80) [10], 
while microglia within DSCL have a phagocytic phenotype associated with the abundance of CD68+ 
amoeboid microglia [11,12]. 
The exact mechanism(s) underlying the pathogenesis of WML remains unknown. However 
chronic cerebral hypoperfusion [13,14], dysfunction of the blood brain-barrier (BBB) [15–17] and 
cortical pathologies have been linked to their formation [18]. WML show arteriolar thickening, 
perivascular widening, capillary loss and perivenous collagenosis, with DSCL in particular 
associated with the expression of high levels of a number of hypoxia response molecules, suggesting 
that vascular insufficiency and consequent hypoperfusion underlie their formation [13]. This is 
further supported by transcriptomic profiling of DSCL, which has confirmed increased expression of 
hypoxia-related genes, and also identified dysregulation of immune-regulatory genes, including 
those involved with antigen presentation, pro-inflammatory cytokine signalling and phagocytosis 
[19]. 
Transcriptomic analyses enable the identification of relevant gene expression changes that are 
often missed in targeted approaches. While histological studies suggest BBB dysfunction, serum 
protein accumulation and microglial activation underlie the pathogenesis of PVL [10,15,20], to date 
no studies have employed transcriptomic analysis to characterise their profile. Therefore, the current 
study interrogated the gene expression profile of PVL using two independent approaches to identify 
novel mechanisms potentially underlying their formation. 
2. Results 
2.1. Histological Characterisation of Periventricular White Matter 
MRI of the formalin-fixed hemisphere was used to guide sampling of the contralateral frozen 
periventricular white matter, and histological characterisation of the sampled frozen blocks was 
performed to confirm the tissue status as non-lesional control periventricular white matter or PVL. 
These frozen blocks were then sampled for transcriptomic analysis. All non-lesional control cases 
displayed preservation of myelin throughout the periventricular region and an intact ependymal 
lining (Figure 1A,B,D,E). In contrast, all PVL cases were characterised by a reduction in luxol fast 
blue (LFB) staining, indicative of myelin attenuation (Figure 1C), and partial denudation of the 
ependyma in four out of seven of the cases (Figure 1F). 
To further characterise the periventricular white matter samples, activated microglia were 
visualised using MHC-II, which immunolabelled the microglial cell body and proximal processes. 
Seven cases of radiologically and histologically-rated non-lesional control white matter contained 
low levels of MHC-II immunoreactive microglia throughout the periventricular region (Figure 1G); 
however, four cases contained high levels of MHC-II expression (Figure 1H). While the MRI and 
histological characterisation had indicated that there was no demyelination, the immunoreactive 
profile of MHC-II suggested microglial activation; therefore, the non-lesional group was 
subsequently subdivided into non-lesional control (no demyelination; low levels of MHC-II 
immunoreactivity, n = 7) and “pre-lesional” cases (no demyelination; high levels of MHC-II+ 
microglia, n = 4). Seven cases of radiologically and histologically-identified PVL contained high levels 
of MHC-II+ microglia (Figure 1I). 
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Figure 1. Histological characterisation of periventricular white matter. Luxol fast blue (LFB) (A,B) and 
H&E staining (D,E) of radiologically normal appearing white matter demonstrated a regular pattern 
of myelin staining across the periventricular region. In contrast, LFB (C) and H&E staining (F) of 
radiologically identified lesional cases displayed a band of periventricular demyelination. MHC-II 
immunostaining of radiologically normal appearing white matter identified cases with minimal 
MHC-II+ microglia ((G), control) but also cases with high levels of MHC-II immunoreactivity ((H), 
“pre-lesional”). Radiologically identified periventricular lesions (PVL) contained high levels of MHC-
II+ microglia (I). Scale bar represents 500 µm in (A–F) and 100 µm in (G–I). 
2.2. Microarray Analysis 
Based on the bioanalyser RNA quality profile, transcriptomic analysis of 18 periventricular 
white matter cases (seven control, four “pre-lesional” and seven PVL) was performed using Human 
Genome U133 Plus 2.0 Arrays, which contain at least one probe for each gene and recognize over 
39,000 genes. Principal component analysis (PCA) showed clear separation of the three groups and 
confirmed there were no sample outliers (Figure 2); quality control (QC) measures were within an 
acceptable range. After setting the stringency parameters to fold change ≥ 1.2 and p value ≤ 0.05, 2256 
genes were significantly differentially expressed in PVL compared to non-lesional control (1378 
upregulated and 878 downregulated); 2649 were significantly differentially-expressed genes in “pre-
lesional” cases compared to PVL (1390 upregulated and 1259 downregulated); and 2398 genes were 
significantly differentially expressed in “pre-lesional” versus non-lesional control cases (1527 
upregulated and 871 downregulated). The microarray datasets are freely available at the Gene 
Expression Omnibus (GEO) public database (accession code GSE157363). 
Int. J. Mol. Sci. 2020, 21, 7924 4 of 21 
 
 
Figure 2. Principle component analysis (PCA) of ageing periventricular transcriptomic datasets. The 
PCA plot of control (blue), “pre-lesion” (yellow) and PVL (pink) shows a separation of differentially-
expressed genes between the groups. 
In PVL compared to non-lesional control periventricular white matter, functional grouping 
analysis with the highest stringency settings identified enrichment of genes that were associated with 
MHC antigen processing and presentation, major histocompatibility II receptor activity and collagen 
IV. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) identified 53 significantly 
dysregulated pathways (Supplementary Materials, Table S1), including immune response-associated 
pathways (Table 1). In PVL, genes associated with antigen processing and presentation (MHC-II) 
were significantly downregulated, including HLA-DRA (probeset 210982_s_at, FC = −1.71, p = 0.0038) 
and CD74 (probeset 1567627_at, FC = −2.67, p = 0.0068). Significant downregulation of genes 
associated with the phagosome was also detected, including FCGR1A (probeset 216951_at, FC = −2.12, 
p = 0.0164). 
Table 1. KEGG pathway analysis of PVL versus control white matter transcriptomic datasets. 
Pathway Count p-Value 
hsa04612: Antigen processing and presentation 20 9.17 × 10
−6 
hsa04145: Phagosome 24 0.003 
hsa04672: Intestinal immune network for IgA production 11 0.004 
hsa04662: B cell receptor signalling pathway 12 0.026 
In “pre-lesional” compared to non-lesional control periventricular white matter, functional 
grouping analysis revealed enrichment of genes associated with calcium signalling, glutamate 
receptor activity, GABA receptor activity and MHC classes I/II-like antigen recognition protein. 
KEGG pathway analysis identified 79 significantly dysregulated pathways (Supplementary 
Materials, Table S2), including immune response-associated signalling pathways (including calcium, 
cAMP and MAPK) and synaptic pathways (including glutamatergic, dopaminergic and cholinergic 
synapses) (Table 2). In “pre-lesional” cases, multiple genes associated with the phagosome, antigen 
processing and antigen presentation were downregulated, including HLA-DPA1 (probeset 213537_at, 
FC = −2.72, p = 0.0004) and HLA-DQB1 (probeset 211654_x_at, FC = −1.76, p = 0.0046). Upregulation of 
multiple genes associated with calcium signalling and synaptic signalling was found, including 
calcium voltage-gated channel subunit alpha 1E (CACNA1EI) (probeset 236013_at, FC = 4.46, p = 0.001; 
probeset 244256_at, FC = 4.11, p = 0.001; probeset 240650_at, FC = 1.31, p = 0.016; probeset 208432_s_at, 
FC = 1.62, p = 0.012) and calcium/calmodulin-dependent protein kinase IV (CAMK4) (probeset 
229029_at, FC = 2.74, p = 0.0008; probeset 241871_at, FC = 3.31, p = 0.0008), along with upregulation of 
genes associated with GABAergic synaptic signalling, including gamma-aminobutyric acid (GABA) 
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A receptor alpha 5 GABRA5 (probeset 206456_at, FC = 7.1, p = 0.0002; probeset 215531_s_at, FC = 3.89, 
p = 0.001; probeset 217280_x_at, FC= 1.6, p = 0.009). 
Table 2. KEGG pathway analysis of “pre-lesional” versus control white matter transcriptomic 
datasets. 
Pathway Count p-Value 
hsa04020:Calcium signalling pathway 42 3.38 × 10−9 
hsa04728:Dopaminergic synapse 34 5.29 ×10−9 
hsa04724:Glutamatergic synapse 30 6.28 × 10−8 
hsa04725:Cholinergic synapse 29 1.29 × 10−7 
hsa04727:GABAergic synapse 23 1.82 × 10−6 
hsa04612:Antigen processing and presentation 20 1.58 × 10−5 
hsa04024:cAMP signalling pathway 34 1.54 × 10−4 
hsa04010:MAPK signalling pathway 40 2.23 × 10−4 
hsa04145:Phagosome 25 0.002 
hsa04062:Chemokine signalling pathway 28 0.005 
hsa04151:PI3K-Akt signalling pathway 45 0.005 
hsa04660:T cell receptor signalling pathway 17 0.011 
hsa04662:B cell receptor signalling pathway 13 0.014 
hsa04068:FoxO signalling pathway 19 0.038 
In “pre-lesional” periventricular white matter compared to PVL, functional grouping analysis 
identified an enrichment of genes associated with GABA receptor activity, adenylate cyclase activity, 
metallothionein and neurotransmitter gated ion channels. KEGG pathway analysis identified 38 
significantly dysregulated pathways (Supplementary Materials, Table S3), including signalling 
pathways (including calcium, cAMP, cGMP and MAPK) and synaptic pathways (including 
glutamatergic, GABAergic and dopaminergic synapses) (Table 3). Significant upregulation of 
multiple genes encoding the calcium signalling pathway was detected in “pre-lesional” 
periventricular white matter, including upregulation of calmodulin 1 and calmodulin 2 (CALM1 and 
CALM2) (probeset 213688_at, FC = 1.59, p = 0.016) and calcium/calmodulin-dependent protein kinase 
II alpha (CAMK2A) (probeset 213108_at, FC = 1.67, p = 0.043; probeset 207613_s_at, FC = 7.06, p = 
0.008); and upregulation of genes associated with glutamatergic signalling, including glutamate 
receptor, ionotropic, N-methyl D-aspartate 1 (GRIN1) (probeset 205915_x_at, FC = 1.45, p = 0.011; 
probeset 211125_x_at, FC = 1.65, p = 0.041; probeset 210781_x_at, FC = 1.82, p = 0.018), glutamate 
receptor, ionotropic, AMPA 2 (GRIA2) (probeset 241172_at, FC = 1.55, p = 0.015) and GRIA3 (probeset 
1569290_s_at, FC = 1.6, p = 0.017; probeset 217565_at, FC = 1.87, p = 0.021; probeset 208032_s_at, FC = 
2.38, p = 0.0005; probeset 230144_at, FC = 2.66, p = 0.004; probeset 206730_at, FC = 2.94, p = 0.006). 
Table 3. KEGG pathway analysis of “pre-lesional” versus PVL transcriptomic datasets. 
Pathway Count p-Value 
hsa04020:Calcium signalling pathway 46 4.71 × 10−11 
hsa04724:Glutamatergic synapse 29 3.97 ×10−7 
hsa04727:GABAergic synapse 21 3.58 × 10−5 
hsa04725:Cholinergic synapse 23 2.30 × 10−4 
hsa04310:Wnt signalling pathway 26 3.83 × 10−4 
hsa04024:cAMP signalling pathway 33 5.36 × 10−4 
hsa04022:cGMP-PKG signalling pathway 28 5.96 × 10−4 
hsa04728:Dopaminergic synapse 22 0.0039 
hsa04010:MAPK signalling pathway 34 0.0143 
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2.3. EnrichR 
The top 1000 significantly differentially-expressed genes in the PVL versus control non-lesional 
white matter dataset were imported into EnrichR to check their relationships with KEGG pathways, 
biological processes, panther pathways and the human gene atlas. The top pathway or functional 
group identified in each analysis included: antigen processing and presentation (KEGG pathway p = 
6.77 × 10−6); inflammation (panther pathway, p = 0.0001); and MHC-II (cellular component p = 0.0001). 
The top 10 pathways/functional groups identified by EnrichR are shown in Table 4. 
Table 4. Enrich R analysis of PVL versus control non-lesional white matter transcriptomic datasets. 
The top 10 pathways/functional groups identified by the analysis are shown below. 
Pathway/Functional Group p-Value 
KEGG pathway  
hsa04612: Antigen processing and presentation 6.77 × 10−6 
hsa05169: Epstein-Barr virus infection 1.06 × 10−4 
hsa05215: Prostate cancer 1.49 × 10−4 
hsa05140: Leishmaniasis 4.58 × 10−4 
hsa05168: Herpes simplex infection 8.04 × 10−4 
hsa05332: Graft-versus-host disease 8.61 × 10−4 
hsa04940: Type I diabetes mellitus 0.0012 
hsa04915: Estrogen signalling pathway 0.0015 
hsa05330: Allograft rejection 0.003 
hsa05164: Influenza A 0.0031 
Panther pathway  
P00031: Inflammation mediated by chemokine and cytokine signalling 1.20 × 10−4 
P00053: T cell activation 0.0068 
P02756: N-acetylglucosamine metabolism 0.0199 
P02776: Serine glycine biosynthesis 0.0199 
P00010: B cell activation 0.0217 
P00007: Axon guidance mediated by semaphorins 0.0257 
P00049: Parkinson disease 0.0359 
P00054: Toll receptor signalling pathway 0.0391 
P00006: Apoptosis signalling pathway 0.0426 
P04386: Histamine H2 receptor mediated signalling pathway 0.0443 
Gene Ontology (cellular component)  
GO:0042613: MHC class II protein complex 1.24 × 10−4 
GO:0016607: nuclear speck 3.02 × 10−4 
GO:0045121: membrane raft 4.73 × 10−4 
GO:0012507: ER to Golgi transport vesicle membrane 5.67 × 10−4 
GO:0030671: clathrin-coated phagocytic vesicle membrane 9.54 × 10−4 
GO:0016606: LYSP100-associated nuclear domain 0.0022 
GO:0010445: nuclear dicing body 0.0022 
GO:0071601: sphere organelle 0.0022 
GO:0016604: nuclear body 0.0022 
GO:0035363: histone locus body 0.0023 
2.4.  Computational Deconvolution of Microglial Gene Expression 
To focus the results on changes in the microglial phenotype, bone marrow stromal cell antigen 
2 (BST2), also referred to as CD317 or tetherin, was used to identify the co-expressed genes associated 
with inactivated microglia (group A), while for activated microglia, TREM2, HLA-DRA, ENTPD1, 
CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (group B). In both activated and 
inactivated microglia groups, 17 genes were co-expressed with the gene set selected (Table 5), which 
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showed similar patterns of expression in the three groups: non-lesional control, “pre-lesion” and PVL 
(Figure 3). Overall analysis of the co-expressed genes suggested similar levels of activated and 
inactivated microglia within PVL and “pre-lesions” compared to non-lesional control white matter, 
with the exception of CD80 which showed a marked decrease in expression in PVL (Figure 3). 
 
Figure 3. Graphical representation of gene annotations in activated and inactivated microglia in 
ageing periventricular white matter. BST2 was used to identify the co-expressed genes associated 
with inactivated microglia (A–A3). For activated microglia, TREM2, HLA-DRA, ENTPD1, CD80, 
CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (B–B3). C: non-lesional control white 
matter; P: “pre-lesional”; L: periventricular lesion. 
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Table 5. Microglial deconvolution. BST2 (CD317) was used to identify the co-expressed genes 
associated with inactivated microglia (group A), while for activated microglia TREM2, HLA-DRA, 
ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (group B). 
Group A (Inactivated Microglia) Group B (Activated Microglia) 
ISG15 HLA-DPB1 
MX1 HLA-DQB1 
IFI44L HLA-DMB 
OAS2 HLA-DPA1 
IFI35 LCP2 
OAS1 FCER1G 
LY6E GBP5 
IFIT1 CYBB 
IFI44 SAMSN1 
UBE2L6 SLAMF8 
IFIT3 MS4A6A 
IRF7 IGSF6 
XAF1 HAVCR2 
RSAD2 TFEC 
OAS3 CD163 
IRF9 FCGR2A 
USP18 MSR1 
2.5.  Validation of Candidate Gene Expression by NanoString nCounter 
Nanostring is a hybridisation-multiplex digital technology which uses capture probes and 
unique color-coded barcode reporter probes to measure a broad range of mRNA in a single reaction 
without the need of reverse transcription of mRNA or amplification of cDNA. 
NanoString data analysis was employed to validate a panel of candidate gene expression 
changes identified in the microarray analysis of PVL versus non-lesional control white matter. 
NanoString analysis confirmed the significant differential expression of seven genes (CCL3 p = 0.008; 
CCR5 p = 0.0002; CD74 p = 0.013; CX3CR1 p = 0.01; IL1B p = 0.0007; JUN p = 0.008; PTGS2 p = 0.007), 
and identified 19 genes which showed the same directional changes to the microarray findings, 
although not reaching statistical significance (Table 6). 
Table 6. Validation of candidate gene expression by NanoString nCounter. 
 Microarray NanoString 
Gene Fold Change p-Value Fold Change p-Value 
AKT3 1.33 0.002 ** 1.52 0.127 
CCL2 −1.7 0.05 * −1.88 0.290 
CCL3 −1.31 0.05 * −16.11 0.008 ** 
CCL4 −1.16 0.060 −5.14 0.098 
CCR5 −1.49 0.01 * −2.17 0.0003 *** 
CD163 −3.27 0.315 −1.07 0.928 
CD74 −2.67 0.006 **  −1.54 0.013 * 
CD8A −1.28 0.016 * −1.23 0.567 
COL6A3 −1.62 0.01 * −1.72 0.074 
CX3CR1 −1.5 0.005 **  −1.64 0.01 * 
CYBB −1.62 0.013 * −1.17 0.577 
EPSTI1 −1.31 0.839 −1.39 0.101 
FCER1G −1.52 0.076 −1.28 0.265 
FGL2 −1.77 0.012 * −1.29 0.190 
FPR1 −2.39 0.017 * −2.82 0.066 
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HLA-DRA −1.71 0.004 ** −1.51 0.071 
IFNAR1 1.79 0.004 ** 1.25 0.190 
IGSF6 −1.27 0.257 −1.12 0.585 
IKBKB 1.38 0.839 1.88 0.097 
IL1A −1.06 0.206 −1.71 0.061 
IL1B −1.34 0.01 * −4.72 0.007 ** 
IRF7 1.04 0.673 −1.04 0.846 
JUN 1.33 0.008 **  1.98 0.008 ** 
MSR1 −1.95 0.023 * −1.06 0.877 
OAS1 −1.12 0.83 1.14 0.644 
PHF21A 1.36 0.008 ** 1.5 0.121 
PTGS2 −1.3 0.011 * −2.59 0.007 ** 
RSAD2 −1.2 0.065 1.09 0.757 
SLAMF8 −1.03 0.679 −1.48 0.327 
* p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001, down-regulated transcripts (pink), up-regulated transcripts (green). 
2.6.  Validation of Candidate Gene Expression by Immunohistochemistry 
To further validate our transcriptomic findings, we selected a panel of four biologically relevant 
genes from pathways highlighted by both the microarray and NanoString datasets (CD74, IL1B, 
CD163, CD86). Expression of proteins encoded by the genes of interest were examined by 
immunohistochemistry (Figure 4), and the immunoreactive area of CD74, IL-1β, CD163 and CD86 
staining in the periventricular white matter was quantified within each group (Table 7). CD74 
immunolabelled microglia with a ramified morphology and were mainly present in the non-lesional 
control group (Figure 4A–C). Expression of CD74 significantly differed across the three groups (p = 
0.002), with non-lesional control periventricular white matter containing significantly higher levels 
of CD74 immunoreactivity compared to both “pre-lesional” (p = 0.033) and PVL (p = 0.003) (Figure 
5A). IL-1β, CD163 and CD86 immunoreactivity was predominantly associated with the cell bodies 
and extending processes of cells morphologically resembling microglia. Expression of IL-1β (p = 0.7), 
CD163 (p = 0.38) and CD86 (p = 0.63) immunoreactivity did not significantly vary across the three 
groups (Figure 5B–D). 
Table 7. Expression of CD74, IL-1β, CD163 and CD86 in ageing periventricular white matter. The 
percentage area of immunoreactivity of each of the markers is shown, median (IQR). 
WM Group Control Pre-Lesional PVL 
CD74 3.47 (3.08–4.15) 1.66 (0.9–2.14) 1.3 (1.13–1.66) 
IL-1β 3.87 (1.91–4.86) 2.76 (1.91–4.07) 3.43 (2.48–4.22) 
CD163 0.93 (0.75–1.21) 0.39 (0.29–1.08) 0.95 (0.59–1.32) 
CD86 4.55 (4.52–5.66) 5.34 (3.98–6.23) 5.04 (3.35–6.03) 
IQR: inter-quartile range. 
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Figure 4. Histological validation candidate gene expression changes. Expression of proteins encoded 
by candidate genes highlighted by both microarray and NanoString datasets was assessed. (A–C) 
CD74, (D–F) IL-1β, (G–I) CD163 and (J–L) CD86 immunolabelled cell bodies and processes of 
microglia in all periventricular white matter groups: non-lesional control white matter (A,D,G,J); 
“pre-lesional” white matter (B,E,H,K); and PVL (C,F,I,L). Scale bar represents 100 µm. 
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Figure 5. Quantitation of the expression of candidates in periventricular ageing white matter. The 
percentage area immunoreactivity of the protein encoded by a panel of candidate genes was assessed 
in the three periventricular white matter groups. (A) CD74 expression was significantly higher in non-
lesional control periventricular white matter compared to both “pre-lesional” (p = 0.033) and PVL (p 
= 0.003). The immunoreactive profiles of (B) IL-1β, (C) CD163 and (D) CD86 did not significantly 
differ across the three groups. *p < 0.05, ***p < 0.005. 
3. Discussion 
Age-associated WML correlate with reductions in information processing speed and executive 
function, and are associated with an increased risk of developing dementia [8,21]. Histological 
characterisation and transcriptomic profiling of DSCL suggest that vascular insufficiency and 
hypoperfusion underlie their formation [13], but to date no comparable studies have interrogated the 
gene expression profile of PVL. The current study employed two independent approaches to 
characterise the transcriptomic signature of PVL, aiming to identify potential mechanisms underlying 
their pathogenesis. We demonstrate that established, demyelinated PVL are associated with 
dysregulation of the immune response, whilst increased signalling is a feature of “pre-lesional” 
periventricular white matter and may represent attempts to prevent lesion formation. 
PVL are characterised by dysfunction of the BBB and significant levels of immune-activated 
MHC-II+ microglia [10,15,17], suggesting that a loss of cerebrovascular integrity and the resulting 
microglial activation contribute to lesion pathology. In the current study, radiologically identified 
PVL and non-lesional control periventricular white matter cases underwent histological validation, 
including assessment of MHC-II immunoreactivity, prior to transcriptomic profiling. As expected, 
demyelination and MHC-II+ microglia are prominent features of PVL; however, a subgroup of 
radiologically normal periventricular white matter cases were identified, which showed no evidence 
of demyelination but contained moderately high levels of MHC-II+ microglia. The transcriptomic 
profile of these cases was subsequently assessed independently and termed “pre-lesional,” although 
it should be acknowledged that it cannot be definitively known whether these cases would have 
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progressed to develop clinically relevant PVL. Extensive detailed histological characterisation studies 
are required to fully elucidate the profile of these “pre-lesions.” 
Microarray analysis indicates that the transcriptome of “pre-lesional” cases is distinct from 
radiologically and histologically control-grade white matter from non-lesional cases, and similarly to 
PVL, is associated with the dysregulation of immune function-associated genes. In contrast to 
increased immunohistochemical detection of MHC-II, several HLA-associated transcripts are 
significantly down-regulated in both “pre-lesion” and PVL compared to non-lesional control white 
matter. It should, however, be noted that mRNA and protein expression can be decoupled in time 
[22,23], and that transcriptomic profiling of post-mortem tissue indicates the gene expression profile 
at one timepoint. While this discordant result appears to argue against the use of transcriptomic 
profiling technologies to identify potential biologically relevant gene expression changes, it has been 
shown that differentially-expressed transcripts have significantly higher correlations between mRNA 
and protein levels when compared to transcripts that are not differentially expressed [23], giving 
confidence for the use of mRNA profiling in the current study. Indeed CD74—a protein that 
associates with MHC-II and is an important chaperone that regulates antigen presentation for the 
immune response—is significantly down-regulated in “pre-lesional” cases and PVL, at both the 
mRNA and protein levels. 
As gene expression profiling was conducted on total tissue extracts, which may have masked 
cell-specific changes in the transcriptome, we performed a computational deconvolution to 
interrogate changes in gene expression specific to microglial phenotypes within “pre-lesions” and 
PVL. BST2 (CD317) is associated with inactivated microglia [24] and diminishes the expression of 
inflammatory genes [25]; therefore, BST2 was selected to identify the co-expressed genes associated 
with inactivated microglia. The phenotypic transformation from homeostatic microglia towards 
reactive microglia in dementia pathologies is associated with TREM2 [26], HLA-DRA [27], ENTPD1 
(CD39) [28], CD80 (B7-1) [29], CD86 (B7-2) [10], CCR5 [30], CD274 [31], ITGAX (CD11c) [32], TIMD4 
[33] and MRC1 [34]. Therefore, these candidates were used in the deconvolution analysis to identify 
co-expressed genes associated with active microglia in “pre-lesions” and PVL. Overall, our data are 
consistent with similar levels of both active and inactive-associated microglial transcripts being 
present in both “pre-lesions” and PVL, with the exception of CD80 (expressed by antigen presenting 
cells), which showed a marked decrease in expression in PVL. Overall, our data demonstrate a 
heterogenous microglial population within periventricular white matter, highlighting the microglial 
diversity in the periventricular regions of the ageing brain and the need to examine an extensive 
panel of markers when assessing the microglial phenotype. 
Expression of a panel of candidate gene expression changes identified in the microarray analysis 
of PVL compared to control white matter was validated using NanoString. This novel, robust 
profiling technology has the ability to analyse low RNA quality and enables the quantification of 
mRNA without the use of reverse transcription or amplification of cDNA [35], which is advantageous 
when assessing post-mortem material. In PVL compared to the non-lesional control group, 65% of 
the genes assessed displayed a non-significant but similar directional change between both platforms, 
and 24% of the genes revealed a significant difference with similar directional change, validating the 
findings of the array analysis. Among the validated gene expression changes, significant down-
regulation of the chemokine receptors CCR5 and CX3CR1, the chemokine CCL3 and pro-
inflammatory cytokine IL1B are features of established PVL. Expressions of these chemoattractant 
cytokines and receptors are a prominent feature of active multiple sclerosis lesions and their animal 
models, where they are primarily associated with active microglia and ongoing demyelination [36–
38]; in contrast, their levels significantly decrease in established PVL. 
Cerebral white matter supports the bidirectional transfer of signals between the cortex and 
subcortical structures, where dysregulation of signalling impacts communication and cognitive 
function [21]. Comparison of the transcriptomic profile of “pre-lesional” white matter with both 
control white matter and PVL indicates significant upregulation of signalling and synaptic pathways. 
Loss of white matter integrity following ischaemic stroke in aged mice is mainly attributed to Ca2+ 
dyshomeostasis, which ultimately induces oligodendrocyte loss and axonal disruption [39]; 
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therefore, the significant increase in calcium signalling in “pre-lesional” white matter may represent 
a potential neuroprotective mechanism to prevent lesion formation. Axons release vesicles containing 
glutamate during the propagation of action potentials [40]. Glutamate receptors are expressed by 
mature oligodendrocytes [41], and communication between axons and myelin has led to the axon–
myelin–synapse hypothesis [42], wherein glutamate signalling is a mechanism whereby adaptive 
myelination occurs in electrically active axons. The current study demonstrates an increase in 
synaptic signalling is a feature of “pre-lesions” which may reflect a mechanism to maintain myelin 
integrity and prevent lesion pathogenesis. 
The current study performed transcriptomic profiling of a small number of cases (seven non-
lesional control, four “pre-lesional” and seven PVL); however, it should be acknowledged that 
interrogation of 12 or more cases per group may be required to detect all of the significant 
differentially-expressed genes [43]. Therefore, as some gene expression changes may not have been 
detected, future research on a larger cohort of cases is required. A further limitation of the current 
study is the interpretation of the transcriptomic datasets with a bias towards assessing the microglial 
phenotype associated with ageing periventricular white matter pathology. The total periventricular 
region isolated by LCM will have contained a heterogeneous population of cells. While several of the 
candidate gene expression changes are associated with microglial functions and phenotypes, 
including HLA-associated transcripts, they are not uniquely associated with microglia and may 
reflect changes in the transcriptomic profiles of other cells, for example, astrocytes. Future research 
is required to confirm which cell population(s) are associated with the candidate genes identified in 
study. 
Age-associated PVL are significantly associated with cognitive decline in the ageing population, 
but very little is known about the mechanisms underlying the pathology of these lesions. Overall, 
our data suggest that established PVL are part of a continuous spectrum of white matter injury, and 
that increased signalling in “pre-lesional” white matter may be a neuroprotective mechanism to 
prevent the pathogenesis of PVL. Future studies focussing on these pathways is required, as they 
may represent a potential therapeutic target to prevent lesion formation. 
4. Materials and Methods 
4.1. Human CNS Tissue 
Frozen human post-mortem CNS tissue was obtained from the CFAS neuropathology cohort, 
following multi-centre Research Ethical Committee (REC) approval (REC Reference number 
15/SW/0246, approved on 10th August 2015). While this cohort is representative of the ageing 
population, the current study was conducted with a case-control design, as previously described [7]. 
MRI of formalin fixed post-mortem coronal brain slices was used to guide case selection and 
sampling of the contralateral frozen hemisphere, using our previously published protocol [19]. A 
modified Schelten’s semi-quantitative rating [44], was used to select 7 PVL and 11 radiologically-
normal-appearing control periventricular white matter cases (Table 8). All radiologically normal 
control samples scored 0 in both periventricular and deep subcortical regions. All PVL samples 
scored 3 in the periventricular MRI rating; three samples scored 0 in the deep subcortical region, three 
samples scored 3 and one sample scored 5. 
Table 8. Cohort demographics. 
Experimental 
Approach Classification Median age (y) (Range) Gender (M/F) PMD (h) (Range) 
Microarray Control (n = 11) 84 (70–89) 4/7 11 (6–42) 
 PVL (n = 7) 89 (85–95) 3/4 28 (7–72) 
NanoString Control (n = 7) 84 (70–89) 2/5 14 (6–42) 
 PVL (n = 5) 88 (85–95) 2/3 28 (18–72) 
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4.2. Histological Characterisation 
Frozen sections (10 µm) were fixed in ice-cold acetone at 4 °C for 10 min and stained with 
haematoxylin and eosin (H&E) or luxol fast blue (LFB) to confirm the presence of PVL or non-lesional 
periventricular white matter. Previous studies have shown that PVL contain significantly high levels 
of MHC-II+ microglia [10]; therefore, immunohistochemistry (IHC) was performed to detect this 
marker of microglial activation using a standard Avidin–biotin complex-horse radish peroxidase 
(ABC-HRP) approach. Antibody conditions and suppliers are shown in Table 9. 
Table 9. Antibody sources and conditions. 
Antibody Isotype Dilution (Time, Temperature) Supplier 
CD163 Monoclonal Mouse IgG 1:100 (1 h RT) Bio-Rad, UK 
CD68 (PG-M1) Mouse, IgG3κ 1:100 (1 h RT) Dako, UK 
CD74 Polyclonal Rabbit IgG 1:200 (1 h RT) Sigma, UK 
CD80/B7-1 Monoclonal Mouse IgG1 1:20 (overnight 4 °C) R&D Systems, UK 
CD86/B7-2 Polyclonal goat IgG 1:20 (overnight 4 °C) R&D Systems, UK 
CX3CR1 Monoclonal Mouse IgG1 1:25 (overnight 4 °C) Biolegend, UK 
IL-1β Polyclonal Rabbit IgG 1:200 (1 h RT) Proteintech, UK 
MHC-II (HLA-DR) Mouse Monoclonal IgG 1:20 (1 h RT) Dako, UK 
Key: h: hour; RT: room temperature; IL-1β: interleukin 1 beta; κ: Kappa. 
4.3. Laser Capture Microdissection (LCM) 
Cryosections (10 µm) were fixed in ice-cold acetone for 3 min before staining with Toluidine 
blue and rinsing with diethylpyrocarbonate (DEPC)-treated water, for 30 s each. Sections were 
dehydrated in a graded series of ethanol (70%, 95%, 100% for 15 s each), cleared in xylene and left to 
air dry in an air flow hood for at least 60 min before LCM. The periventricular region of interest was 
isolated using a PixCell II laser-capture microdissection system (Arcturus BioScience, Mountain 
View, CA, USA), and CapSure macro caps (Arcturus Engineering, Mountain View, CA, USA). Briefly, 
LCM of the periventricular white matter was performed using 30 µm laser spot size and a pulse 
power of 65–90 mW. Following microdissection, RNA was extracted using the PicoPure RNA 
extraction kit, according to manufacturer’s protocol (Arcturus BioScience, Mountain View, CA, USA). 
Pre- and post-LCM RNA quality was assessed using a Bioanalyser (Agilent, CA, USA). 
4.4. Microarray 
RNA was prepared according to the GeneChip 3′ IVT express amplification protocol 
(Affymetrix, Stockport, UK). RNA was reverse transcribed to produce single-stranded cDNA by 
annealing the total RNA with an oligo-d(T) primer with a T7 polymerase binding site. The cDNA 
was converted into double-stranded cDNA by DNA polymerase and RNAse H. Biotin-labelled cRNA 
was made using an in vitro transcription (IVT) labelling kit. Following clean-up and purification of 
the biotin labelled cRNA, samples were checked using the bioanalyzer to ensure sufficient RNA had 
been generated (Agilent Bioanalyzer 2100). Samples (12 µg) were analysed using GeneChip Human 
U133 Plus 2.0 arrays (Affymetrix, Stockport, UK). 
4.5. Transcriptomic Analysis of Microarrays 
Quality control (QC) analysis was performed to confirm amplification, hybridisation, expression 
of housekeeping genes and signal intensity using Affymetrix Expression Console software 
(Affymetrix®, Stickport, UK). Transcriptome Analysis Console (TAC) software version 4.1.1 
(Affymetrix®, Stockport, UK) was used to analyse and compare the gene expression profile of the 3 
groups. Genes were considered significantly differentially expressed if they showed a minimum fold 
change (FC) ≥ +/-1.2 and p ≤ 0.05. Qlucore Omics Explorer (Qlucore, Lund, Sweden) was used to 
identify the distribution of the samples using principal component analysis (PCA). The significantly 
differentially-expressed genes were analysed using the Database for Annotation Visualisation and 
Integrated Discovery (DAVID) annotation website version 6.8, identifying the key gene expression 
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changes in both pathways and functional groups. Annotated genes were filtered using the highest 
stringency settings to obtain high specificity and minimizing the rate of false-positives. Subsequent 
analysis focussed on the top 1000 differentially-expressed genes from each comparison group, and 
they were analysed using EnrichR, an online tool which aids clustering of the genes based on their 
similar functions. Affymetrix probe IDs were converted into Entrez Gene IDs using Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) version 6.8 Gene ID conversion tool 
(david.ncifcrf.gov). 
4.6. Deconvolution of the Microglial Transcriptome 
To interrogate microglial function within the periventricular region, we performed a 
computational deconvolution of the transcriptomic data [45]. We used cell-type-specific markers for 
activated and inactivated microglia based on single-cell mass cytometry of the experimental allergic 
encephalomyelitis mouse model [24], as shown in Table 10. These markers were used to define co-
expression networks which were constructed in GeneMANIA (http://www.genemania.org). The 
parameters used were as follows: maximum resultant genes: 20; maximum resultant attributes: 10; 
and the co-expression category used for gene interconnection [46]. As a final validation, co-expression 
networks focussed on microglial subtypes associated with human CNS cells using an independent 
dataset (http://www.brainrnaseq.org/) [47]. 
Table 10. Microglial gene signature: Group A (inactivated) and Group B (activated). 
 Gene Symbol Gene Name 
Group A CD317 (BST2) Bone marrow stromal cell antigen 2 
Group B 
CD39 (ENTPD1) Ectonucleoside Triphosphate Diphosphohydrolase 1 
HLA-DRA Major Histocompatibility Complex, Class II, DR Alpha 
CD86 Cluster of differentiation 86 
CD80 Cluster of differentiation 80 
CD274 Cluster of differentiation 274 
TIMD4 T Cell Immunoglobulin and Mucin Domain Containing 4 
CD11C (ITGAX) Integrin Subunit Alpha X 
TREM2 Triggering Receptor Expressed on Myeloid Cells 2 
CCR5 C-C chemokine receptor type 5 
MRC1 Mannose Receptor C-Type 1 
4.7. Validation of Gene Expression Changes—NanoString 
Validation of key changes in the gene expression profiles identified by the microarray analysis 
was conducted using NanoString, an independent platform which enables the quantification of 
mRNA without the use of reverse transcription or amplification of cDNA [35]. The gene expression 
profiles of 9 samples (4 control and 5 PVL) were analysed using a customised CodeSet human gene 
panel consisting of 29 inflammation, antigen processing and presentation related genes, and 3 
housekeeping genes (NanoString Technologies, Seattle, WA, USA), as shown in Table 11. Briefly, 50 
ng of RNA extracted from each LCM-ed periventricular white matter region was added to the 
CodeSet in hybridisation buffer and incubated at 65 °C for 22 h in a thermocycler. Raw data (RCC 
files) were analysed using NanoString data analysis software nSolver v4.0.70 (NanoString 
Technologies, Seattle, WA, USA). Data were normalized to the geometric mean of housekeeping 
genes in the designed CodeSet. Both the Affymetrix and NanoString datasets were compared to 
assess expression of the validation candidates. 
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Table 11. Nanostring validation candidates. 
Function Gene Symbol Gene Name 
Inflammation AKT3 
V-akt murine thymoma viral oncogene homolog 3/RAC-gamma 
serine/threonine-protein kinase 
 CCL2 C-C motif chemokine ligand 2 
 CCL3 C-C motif chemokine ligand 3 
 CCL4 C-C motif chemokine ligand 4 
 CCR5 C-C motif chemokine receptor 5 (gene/pseudogene) 
 COL6A3 Collagen type VI alpha 3 chain 
 CX3CR1 C-X3-C motif chemokine receptor 1 
 IFNAR1 Interferon alpha and beta receptor subunit 1 
 IKBKB Inhibitor of nuclear factor kappa B kinase subunit beta 
 IL1A Interleukin 1 alpha 
 IL1B Interleukin 1 beta 
 JUN Jun proto-oncogene, AP-1 transcription factor subunit 
 PTGS2 Prostaglandin-endoperoxide synthase 2 
Antigen processing  
and presentation 
CD74 CD74 molecule, HLA class II histocompatibility antigen gamma chain 
HLA-DRA Major histocompatibility complex, class II, DR alpha 
 CD8A CD8a molecule, T-cell surface glycoprotein CD8 alpha chain 
 CD163 CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130 
CD14 Monocytes EPSTI1 Epithelial stromal interaction protein 1 
 FGL2 Fibrinogen like 2 
 FPR1 Formyl peptide receptor 1 
 IGSF6 Immunoglobulin superfamily member 6 
 PHF21A PHD finger protein 21A 
Inactivated Microglia 
IRF7 Interferon regulatory factor 7 
OAS1 2’-5’-oligoadenylate synthetase 1 
 RSAD2 Radical S-adenosyl methionine domain containing 2 
Activated Microglia FCER1G Fc fragment of IgE receptor Ig 
 MSR1 Macrophage scavenger receptor 1 
 SLAMF8 SLAM family member 8 
 CYBB Cytochrome b-245, beta polypeptide 
Housekeeping Genes 
ACTB Actin cytoplasmic 1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
 RPLP0 60S acidic ribosomal protein P0 
4.8. Validation of Gene Expression Changes—Immunohistochemistry 
To further validate the gene expression changes identified in the microarray analysis, expression 
of the protein encoded by a panel of candidate genes was assessed by immunohistochemistry using 
a standard ABC-HRP approach. The antibody details are shown in Table 9. Selected regions of 
interest were marked on H&E sections and mapped onto consecutive immunostained slides. 
Quantification of specific immunoreactivity was performed by capturing bright-field microscopic 
images within the marked area using a Nikon Eclipse 80i microscope. The image was thresholded 
and the immunoreactive area of the field determined per total area examined. Image capture and 
analysis was performed using Analysis^D software (Nikon, Kingston Upon Thames, UK). 
Immunohistochemical data were not normally distributed and did not show equality of variances 
between groups using the Shapiro–Wilk test; therefore, analyses were performed using non-
parametric methods. Statistical comparisons of quantitative data between groups were carried out 
using the Kruskal–Wallis test using SPSS software version 26.0 (SPSS Inc., Chicago, IL, USA). In the 
case of a significant result, the p value was adjusted for multiple testing using the Bonferroni 
correction method and considered significant if p < 0.05. 
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Abbreviations 
ABC-HRP avidin-biotin complex-horse radish peroxidase 
ACTB actin cytoplasmic 1 
AKT3 V-akt murine thymoma viral oncogene homolog 3 
BBB blood brain-barrier 
BST2 CD317, tethrin 
CACNA1E calcium voltage-gated channel subunit alpha 1E 
CALM calmodulin 
CAMK2A calcium/calmodulin-dependent protein kinase II alpha 
CAMK4 calcium/calmodulin-dependent protein kinase IV 
cAMP cyclic adenosine monophosphateP 
CCL2 C-C motif chemokine ligand 2 
CCL3 C-C motif chemokine ligand 3 
CCL4 C-C motif chemokine ligand 4 
CCR5 C-C motif chemokine receptor 5 (gene/pseudogene) 
CD163 CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130 
CD274 cluster of differentiation 274, programmed death-ligand 1 
CD74 CD74 molecule, HLA class II histocompatibility antigen gamma chain 
CD80 co-stimulatory molecule B7-2 
CD86 cluster of differentiation 86, B7-2 
CD8A CD8a molecule, T-cell surface glycoprotein CD8 alpha chain 
cDNA complementary DNA 
CFAS Cognitive Function and Ageing Study 
CNS central nervous system 
COL6A3 collagen type VI alpha 3 chain 
CX3CR1 C-X3-C motif chemokine receptor 1 
CYBB cytochrome b-245, beta polypeptide 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DEPC diethylpyrocarbonate 
DSCL deep subcortical lesions 
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 
EPSTI1 epithelial stromal interaction protein 1 
FCER1G Fc fragment of IgE receptor Ig 
FCGR1A Fc fragment of immunoglobulin gamma Fc receptor 1A 
FCGR2A Fc fragment of immunoglobulin gamma Fc receptor 2A 
FGL2 fibrinogen like 2 
FPR1 formyl peptide receptor 1 
GABA gamma-aminobutyric acid 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GBP5 guanylate-binding protein 5 
GEO gene expression omnibus 
GRIA glutamate receptor, ionotropic, AMPA 
GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 
H&E haematoxylin and eosin 
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HAVCR2 hepatitis A virus cellular receptor 2 
HLA-DMB major histocompatibility complex, class II, DM beta 
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 
HLA-DRA major histocompatibility complex, class II, DR alpha 
IFI35 interferon induced protein 35 
IFI44 interferon induced protein 44 
IFI44L interferon induced protein 44-like 
IFIT1 interferon induced protein with tetratricopeptide repeats 1 
IFIT3 interferon induced protein with tetratricopeptide repeats 3 
IFNAR1 interferon alpha receptor subunit 1 
IGSF6 immunoglobulin superfamily member 6 
IHC immunohistochemistry 
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta 
IL1A interleukin 1 alpha 
IL1B interleukin 1 beta 
IRF7 interferon regulatory factor 7 
IRF9 interferon regulatory factor 9 
ISG15 interferon-stimulated gene 15 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit), CD11c 
IVT in vitro transcription 
JUN jun proto-oncogene, AP-1 transcription factor subunit 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LCM laser capture microdissection 
LCP2 lymphocyte cytosolic protein 2 
LFB luxol fast blue 
LY6E lymphocyte antigen 6E 
MAPK mitogen-activated protein kinase 
MHC-II major histocompatibility complex class II 
MRC1 mannose receptor C-type 1 
MRI magnetic resnance imaging 
mRNA messenger ribonucleic acid 
MS4A6A membrane spanning 4-domains A6A 
MSR1 macrophage scavenger receptor 1 
MX1 MX dynamin like GTPase 1 
OAS1 2’-5’-oligoadenylate synthetase 1 
OAS2 2’-5’-oligoadenylate synthetase 2 
OAS3 2’-5’-oligoadenylate synthetase 3 
PCA principal component analysis 
PHF21A PHD finger protein 21A 
PI3K-Akt phosphatidylinositol 3-kinase-protein kinase  
PTGS2 prostaglandin-endoperoxide synthase 2 
PVL periventricular lesions  
QC quality control 
REC research ethics committee 
RPLP0 60S acidic ribosomal protein P0 
RSAD2 radical S-adenosyl methionine domain containing 2 
RT room temperature 
SAMSN1 SAM domain, SH3 domain and nuclear localisation signals 1 
SLAMF8 SLAM family member 8 
TAC transcriptome analysis console 
TFEC transcription factor EC 
TREM2 triggering receptor expressed on myeloid cells 2 
UBE2L6 ubiquitin conjugating enzyme E2 L6 
USP18 ubiquitin specific peptidase 18 
WM white matter 
WML white matter lesions 
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XAF1 XIAP-associated factor 1 
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